Media coverage about Genetic Technologies (NASDAQ:GENE) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genetic Technologies earned a news impact score of 0.12 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.2319007235448 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Genetic Technologies (NASDAQ:GENE) opened at $1.08 on Tuesday. Genetic Technologies has a one year low of $0.70 and a one year high of $1.79.
COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/26/genetic-technologies-gene-earns-media-sentiment-score-of-0-12.html.
About Genetic Technologies
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.